—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Regeneron Pharmaceuticals Inc (REGN) — chart, structure and Closelooknet read

The Closelooknet read

Regeneron discovers, develops, manufactures and sells medicines across eye disease, immune and inflammatory conditions, cardiovascular and metabolic disorders, neurological and infectious disease, rare disease, cancer and blood disorders. Its marketed products include an eye injection for macular degeneration and related retinal conditions, an injection for atopic dermatitis and asthma, a skin-cancer treatment, a cholesterol-lowering injection and a rheumatoid arthritis treatment.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for REGN, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-11-10

DayWeekMonth3 months
REGN−0.4%−5.9%+20.1%+14.8%
Longevity & Healthspan−0.3%−1.6%+3.9%—
HALO Growth 100−1.0%−0.1%+1.9%—

Against the index: 5.8 pts behind on the week, 18.2 pts ahead on the month; against its Longevity & Healthspan sleeve 16.2 pts ahead on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Mentioned on Closelooknet 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelooknet

Where REGN appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 48/100 · S&P 500 fund at 51, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-10
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 67th percentile of the window, -18.1% over 20 sessions. Factor regime → 2026-11-10
  • Sector × region Health care in US: +2.6% week · +9.8% month · +12.6% quarter · +32.1% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-10
  • Sovereign pressure Index -1.67 · down 1.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-09
How it trades on rate days beta 0.79 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How REGN has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.79 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Regeneron Pharmaceuticals Inc moved 0.79% on average · correlation 0.22 · higher than 68% of US names
  • Beta, last 3 months 1.16 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.88% on average against −0.72% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.42% TLT −1.32% that day 2026-11-10

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against REGN on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Regeneron Pharmaceuticals Inc

REGN in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Regeneron discovers, develops, manufactures and sells medicines across eye disease, immune and inflammatory conditions, cardiovascular and metabolic disorders, neurological and infectious disease, rare disease, cancer and blood disorders. Its marketed products include an eye injection for macular degeneration and related retinal conditions, an injection for atopic dermatitis and asthma, a skin-cancer treatment, a cholesterol-lowering injection and a rheumatoid arthritis treatment. It also runs research partnerships covering RNA-interference, gene-editing and radiopharmaceutical approaches with several smaller biotech firms. The company is based in Tarrytown, United States.
Where it sits in the stack
Regeneron carries no seat in our chip-focused index; it sits in the Longevity & Healthspan sleeve of the HALO Growth 100, our growth index outside the megacaps, alongside firms building treatments and diagnostics tied to ageing populations.
Who it is priced against
Closelooknet's peer group places it with GLP-1 leaders, gene-editing platforms, diagnostics-at-scale firms and other biopharma compounders, on the view that demographics sets the pace of demand; the names include Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Amgen, Illumina, Zealand Pharma, Natera and Gerresheimer. The market also compares it with Pfizer.
Why Closelooknet tracks it
It holds seats in the HALO Growth 100 and the Nasdaq-100. It carries a Closelooknet score built across three modules so far, with quality reading strongest and valuation reading weakest. The diary quoted it once, in a Midday 10 edition, as one of several health-care names appearing on a large-cap new-high list.
What the diary watches
Whether the research collaborations on gene-editing and RNA-interference begin producing marketed products, and whether that shifts the valuation module away from being the weakest reading.

Regeneron Pharmaceuticals Inc (REGN) trades on US exchanges, classified under Healthcare. Constituent of HALO Growth 100.

The Closelooknet company score reads 64/100 composite (momentum 84, quality 72, valuation 45) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 6 analyst actions on the wire · latest: price target by Baird, 2026-10-30 · last print 2026-10-30

The Street on this name

Analyst actions and the latest print for REGN from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Baird — target 875 Target set to $875 (-5.7% to spot) 2026-10-30
  • Price target UBS — target 978 Target set to $978 (+25.6% to spot) 2026-10-14
  • Price target Truist — target 780 from 772 Target raised to $780 from $772 (+4.3% to spot) 2026-10-07
  • Latest print EPS 20.07 against 16.51 expected — a +21.6% beat 2026-10-30

6 actions on the analyst wire since 2026-08-13: 6 target changes. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 0.40%, quarterly · buybacks 3.97 bn USD in FY2025

Dividends and capital return

What REGN pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 3.70 USD per share · a 0.40% yield on the 2026-11-10 close 4 distributions, paid quarterly 2026-11-10
  • Change on the year +40.1% against the prior twelve months prior twelve months 2.64 USD per share
  • Last distribution 0.94 USD per share as the price series records it, within days of the ex-date 2026-08-18
  • By calendar year 2025: 3.52 USD (partial) · 2026: 2.82 USD to date first distribution recorded in the three-year window: 2025-02-20
  • Dividends paid, FY2025 370 m USD 7% of earnings
  • Buybacks, FY2025 3.97 bn USD 4.3% of today's market value
  • Share count −5.6% in FY2025 994 m USD of stock-based compensation in the year
  • Capital returned 4.34 bn USD · 106% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-11

Quick answers

What is Regeneron Pharmaceuticals Inc (REGN)?

Regeneron Pharmaceuticals Inc trades as REGN on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-11.

Is REGN in a Closelooknet index?

Yes — Regeneron Pharmaceuticals Inc is a constituent of HALO Growth 100, as of 2026-11-11.

What is Regeneron Pharmaceuticals Inc's Closelooknet composite score?

64 out of 100, with momentum 84, quality 72 and valuation 45 sub-scores, as of 2026-11-11. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does REGN trade against its moving averages?

Regeneron Pharmaceuticals Inc trades 14.0% above its 50-day and 23.8% above its 200-day moving average (8.8% above its 20-day). As of 2026-11-09 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is REGN doing against its Closelooknet index?

Over the past month Regeneron Pharmaceuticals Inc is +20.1% against +1.9% for the HALO Growth 100 — 18.2 points ahead of its index, as of 2026-11-10. Its Longevity & Healthspan sleeve is +3.9% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Regeneron Pharmaceuticals Inc compare with its peers?

Against its peer group (HALO Growth 100 · Longevity & Healthspan), Regeneron Pharmaceuticals Inc (REGN) sits 7.2% below its 52-week high, 14.0% above its 50-day average; Eli Lilly and Company (LLY) is 2.8% below, Zealand Pharma A/S (ZEAL.CO) is 55.9% below, Illumina Inc (ILMN) is 28.6% below, as of 2026-11-09. Put any of them next to REGN in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Regeneron Pharmaceuticals Inc trade when bond yields rise?

Over the past year Regeneron Pharmaceuticals Inc had a beta of 0.79 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 68% of US names. On the 10 sessions in which long bonds fell most it moved −0.88% on average, against −0.72% for the S&P 500. As of 2026-11-10; The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Regeneron Pharmaceuticals Inc?

Regeneron Pharmaceuticals Inc appears in 1 Closelooknet piece as of 2026-11-11, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelooknet said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Regeneron Pharmaceuticals Inc do?

Regeneron discovers, develops, manufactures and sells medicines across eye disease, immune and inflammatory conditions, cardiovascular and metabolic disorders, neurological and infectious disease, rare disease, cancer and blood disorders. Its marketed products include an eye injection for macular degeneration and related retinal conditions, an injection for atopic dermatitis and asthma, a skin-cancer treatment, a cholesterol-lowering injection and a rheumatoid arthritis treatment. It also runs research partnerships covering RNA-interference, gene-editing and radiopharmaceutical approaches with several smaller biotech firms. Closelooknet's peer group places it with GLP-1 leaders, gene-editing platforms, diagnostics-at-scale firms and other biopharma compounders, on the view that demographics sets the pace of demand; the names include Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Amgen, Illumina, Zealand Pharma, Natera and Gerresheimer. The market also compares it with Pfizer. (Company snapshot of 2026-09-17.)

Where does Regeneron Pharmaceuticals Inc sit in the AI build-out?

Regeneron carries no seat in our chip-focused index; it sits in the Longevity & Healthspan sleeve of the HALO Growth 100, our growth index outside the megacaps, alongside firms building treatments and diagnostics tied to ageing populations. It holds seats in the HALO Growth 100 and the Nasdaq-100. It carries a Closelooknet score built across three modules so far, with quality reading strongest and valuation reading weakest. The diary quoted it once, in a Midday 10 edition, as one of several health-care names appearing on a large-cap new-high list. (Company snapshot of 2026-09-17.)

Does Regeneron Pharmaceuticals Inc pay a dividend?

Regeneron Pharmaceuticals Inc has paid 3.70 USD per share over the last twelve months, paid quarterly, a trailing yield of 0.40% on the 2026-11-10 close; the last distribution recorded in the price series was 0.94 USD on 2026-08-18. In fiscal 2025 the company paid 370 m USD in dividends and bought back 3.97 bn USD of its own shares, 106% of that year’s free cash flow. The share count fell 5.6% over the fiscal year. As of 2026-11-10; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Regeneron Pharmaceuticals Inc recently?

The most recent analyst action on Regeneron Pharmaceuticals Inc on the Closelooknet wire is a price target by Baird on 2026-10-30 (target 875). 6 actions on the analyst wire since 2026-08-13: 6 target changes. Its latest earnings print on the wire, 2026-10-30: EPS 20.07 against 16.51 expected — a +21.6% beat. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for REGN, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.